CYAD-01, an autologous NKG2D-based CAR T-cell therapy, in relapsed or refractory acute myeloid leukaemia and myelodysplastic syndromes or multiple myeloma (THINK): haematological cohorts of the dose escalation segment of a phase 1 trial.
Lancet Haematol
; 10(3): e191-e202, 2023 Mar.
Article
in En
| MEDLINE
| ID: mdl-36764323
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Myelodysplastic Syndromes
/
Leukemia, Myeloid, Acute
/
Multiple Myeloma
Limits:
Humans
Language:
En
Journal:
Lancet Haematol
Year:
2023
Type:
Article